Blog
RSS FeedPosted by Michael Wonder on 04 May 2022
Methods paper: new version 6.1 becomes effective – English translation now available
2 May 2022 - The amendments concern, among other things, the approach to evidence searches for clinical practice guidelines. New ...
Posted by Michael Wonder on 21 Apr 2022
European collaboration on health technology assessment: looking backward and forward
19 April 2022 - The establishment of health technology assessment has been an important topic in Europe for many years. ...
Posted by Michael Wonder on 19 Apr 2022
Supply related data in manufacturer dossiers: things are not going smoothly yet
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
Posted by Michael Wonder on 19 Apr 2022
Lenvatinib and pembrolizumab in endometrial cancer: patients live significantly longer
19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to ...
Posted by Michael Wonder on 12 Apr 2022
Prospective measures to combat rising drug prices in Germany
13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...
Posted by Michael Wonder on 15 Mar 2022
Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...
Posted by Michael Wonder on 01 Mar 2022
Triple negative breast cancer: survival benefit with sacituzumab govitecan
1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, ...
Posted by Michael Wonder on 20 Feb 2022
Assessing transferability in systematic reviews of health economic evaluations – a review of methodological guidance
20 February 2022 - For assessing cost effectiveness, health technology assessment organisations may use primary economic evaluations or systematic reviews of ...
Posted by Michael Wonder on 15 Feb 2022
Pembrolizumab in combination with chemotherapy: significant additional benefit in advanced squamous cell carcinoma of the oesophagus
15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an ...
Posted by Michael Wonder on 02 Feb 2022
New EU regulation on health technology assessment of cancer medicines
1 February 2022 - On Dec 15, 2021, the EU adopted a new regulation to harmonise health technology assessment of new ...
Posted by Michael Wonder on 31 Jan 2022
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project
28 January 2022 - This article aims at describing the most relevant elements of the drug development process in the paediatric ...
Posted by Michael Wonder on 30 Jan 2022
Building a model of health technology assessment co-operation: lessons learned from EUnetHTA joint action 3
28 January 2022 - The European Network for Health Technology Assessment (EUnetHTA) was established in 2006. During its final project phase ...
Posted by Michael Wonder on 24 Jan 2022
Method paper: new version 6.1 comes into force
24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...
Posted by Michael Wonder on 20 Jan 2022
The G-BA classifies three drugs as reserve antibiotics
20 January 2022 - The Federal Joint Committee (G-BA) today exempted three drugs classified as reserve antibiotics from the regular early ...
Posted by Michael Wonder on 20 Jan 2022
Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer
20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...